AssetMark’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.56K Buy
+24
New +$1.75K ﹤0.01% 3124
2026
Q2
– Sell
-3
Closed -$204 – 3638
2026
Q1
$204 Buy
+3
New +$212 ﹤0.01% 3320
2021
Q2
– Sell
-42
Closed -$2K – 1498
2021
Q1
$2K Buy
42
+2
+5% +$119 ﹤0.01% 1197
2020
Q4
$2K Hold
40
– – ﹤0.01% 1230
2020
Q3
$2K Sell
40
-8
-17% -$394 ﹤0.01% 1142
2020
Q2
$2K Buy
48
+16
+50% +$786 ﹤0.01% 1114
2020
Q1
$1K Buy
+32
New +$1.61K ﹤0.01% 1288

Other funds holding PTCT

AssetMark's PTCT Position: Q3 2026 in Review

AssetMark opened a new position in PTC Therapeutics (PTCT) in Q3 2026: 24 shares worth $1.56K. The stake represents ﹤0.01% of the portfolio and ranks #3124 among its holdings. This is a return to the name: AssetMark previously reported a position in PTCT as recently as Q1 2026.

AssetMark first reported a position in PTCT in Q1 2020 and has held it in 7 quarters since. The position peaked at $2K in Q1 2021. 275 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • AssetMark held 24 shares of PTC Therapeutics worth $1.56K as of Q3 2026.
  • PTC Therapeutics was a new AssetMark position in Q3 2026.
  • PTC Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3124 holding.
  • AssetMark first reported a position in PTC Therapeutics in Q1 2020 and has held it in 7 quarters since.
  • AssetMark's PTC Therapeutics position peaked at $2K in Q1 2021.
  • 275 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.